benzofuran-2-carboxylic acid 4-carbamimidoyl-benzylamide | 1005479-64-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: benzofuran-2-carboxylic acid 4-carbamimidoyl-benzylamide
• 英文别名: N-[(4-carbamimidoylphenyl)methyl]-1-benzofuran-2-carboxamide
• CAS: 1005479-64-0
• 化学式: C₁₇H₁₅N₃O₂
• 分子量: 293.325
• InChiKey: FZJOIHKAXPWTFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  92.1
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• INHIBITORS OF PLASMA KALLIKREIN
  申请人：Sinha Sukanto

  公开号：US20080038276A1

  公开（公告）日：2008-02-14

  The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment.

  本发明提供了一种抑制血浆卡利肌酶（PK）活性的化合物，以及预防和治疗PK依赖性疾病或情况中凝血酶形成的方法，例如，在纤溶治疗后。
• METHODS FOR TREATMENT OF KALLIKREIN-RELATED DISORDERS
  申请人：Aiello Lloyd P.

  公开号：US20110065757A1

  公开（公告）日：2011-03-17

  We have identified classes of kallikrein inhibitors as compounds that are useful in the reduction of vascular permeability (e.g., retinal vascular permeability and cerebral vascular permeability) and astrocyte activation. Diseases and conditions associated with increased vascular permeability include diabetic retinopathy, hemorrhagic stroke, and macular edema. Diseases and conditions associated with astrocyte activation include Alzheimer's disease, multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, stroke, epilepsy, and brain trauma.
• METHOD FOR REDUCING BLOOD PRESSURE USING INHIBITORS OF PLASMA KALLIKREIN
  申请人：Feener Edward P.

  公开号：US20110318359A1

  公开（公告）日：2011-12-29

  The present invention relates to methods of reducing blood pressure in a subject by administering a plasma kallikrein inhibitor.
• US7625944B2
  申请人：——

  公开号：US7625944B2

  公开（公告）日：2009-12-01
• US7977380B2
  申请人：——

  公开号：US7977380B2

  公开（公告）日：2011-07-12